Last year in September before the beginning of one of the most severe flu season in history, Medicago, a biotech Company from Canada initiated phase 3 of the flu vaccine clinical trial. This vaccine was primarily manufactured from tobacco plants, and the Canadian company is looking prove that its unique method of production will reduce the time it takes to make vaccines—and that it will also be more efficient.
Medicago has been relentless in its efforts to revolutionize the flu vaccine but has been facing challenges due to the wily nature of the virus. The major issue with flu is how quick it mutates. This characteristic allows it to transform into other subtypes of the same virus thus becoming resistant to the vaccine. Moreover, the company wishes to do away with the slow method of growing flu vaccines in eggs which according to studies increase the tendency of the virus used in the production process to mutate thus distancing it from the circulating strains.
Vaccine experts at Medicago are determined that their technology will produce a vaccine that can spot and destroy circulating viruses (even when they undergo mutation). The scientists are using “virus-like particles” that are similar in structure …Continue reading